Allergy Therapeutics

We provide information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with a special focus on allergy vaccination (also known as specific immunotherapy or desensitisation therapy). Allergy vaccination is a successful treatment that deals with the underlying cause of allergies and not just the symptoms! Allergy Therapeutics has a long-term commitment to the development of innovative therapies for allergy treatment and allergy prevention.
Worthing, GB
Size (employees)
440 (est)+18%
Allergy Therapeutics was founded in 1934 and is headquartered in Worthing, GB

Allergy Therapeutics Office Locations

Allergy Therapeutics has an office in Worthing
Worthing, GB (HQ)
Dominion Way

Allergy Therapeutics Data and Metrics

Allergy Therapeutics Financial Metrics

Allergy Therapeutics's revenue was reported to be £48.5 m in FY, 2016 which is a 12% increase from the previous period.

Revenue (FY, 2016)

48.5 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

34.4 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

(13.1 m)

Market capitalization (25-Jul-2017)

181.7 m

Closing share price (25-Jul-2017)


Cash (30-Jun-2016)

23.4 m
Allergy Therapeutics's current market capitalization is £181.7 m.
GBPFY, 2013FY, 2014FY, 2015FY, 2016


39.3 m42 m43.2 m48.5 m

Revenue growth, %


Cost of goods sold

12 m12 m12.2 m14.1 m

Gross profit

27.3 m30 m31.1 m34.4 m

Gross profit Margin, %


Operating expense total

26.7 m28.8 m30.3 m46.4 m

Pre tax profit

1.1 m654 k(12.1 m)

Net Income

741 k108 k(13.1 m)
GBPFY, 2014FY, 2015FY, 2016


2 m21.2 m23.4 m

Accounts Receivable

2.8 m3.1 m4.7 m

Current Assets

14.2 m33.8 m37.6 m


10.4 m11.9 m13.7 m


3.8 m5 m5.4 m

Total Assets

28.4 m50.7 m56.7 m

Accounts Payable

2.5 m2.8 m3.1 m

Current Liabilities

6.5 m7.4 m12.5 m

Total Liabilities

13.3 m16.2 m26.4 m

Retained Earnings

741 k108 k(13.1 m)

Total Equity

15.1 m34.5 m30.3 m

Financial Leverage

1.9 x1.5 x1.9 x
GBPFY, 2014FY, 2015FY, 2016

Cash From Operating Activities

2.2 m3.1 m(11.8 m)

Cash From Financing Activities

20.1 m12.5 m

Income Taxes Paid

(343 k)(546 k)(1 m)
GBPY, 2016


130.1 k

Financial Leverage

1.9 x

Allergy Therapeutics Market Value History

Allergy Therapeutics News and Updates

Allergy Therapeutics Company Life and Culture

You may also be interested in